Therapy of ulcerative colitis

Current Opinion in Gastroenterology

Volumn 20, Issue 4, 2004, Pages 345-350

  Hanauer, Stephen B ^a   Sparrow, Miles ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Aminosalicylates; Biologic therapy; Cyclosporine; Immunosuppressive therapy; Probiotics; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALPHA INTERFERON; AMINOSALICYLIC ACID; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR; GLUCOCORTICOID; INFLIXIMAB; MAGNESIUM; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; PROBIOTIC AGENT; SALICYLIC ACID; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR;

ANEMIA; APHERESIS; BLEEDING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG FORMULATION; EVALUATION; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; ILEITIS; INFECTION; INFLAMMATION; INFLUENZA; KIDNEY INJURY; LEUKOCYTE; PARESTHESIA; PROGNOSIS; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; ULCERATIVE COLITIS;

EID: 3042588106     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200407000-00008     Document Type: Review

References (32)

1. Eaden J: The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003, 18(Suppl 2):15-21. An excellent review article providing reasonable evidence that aminosalicylates, which are cheap and nontoxic, may have a role as chemopreventive agents in patients with UC.
2. Rubin DT, Djordjevic A, Huo D, et al.: Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis [Abstract]. DDW 2003.
3. Reinacher-Schick A, Seidensticker F, Petrasch S, et al.: Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000, 32:245-254.
4. Kruis W, Bar-Meir S, Feher J, et al.: The optimal dose of 5-aminosaliclic acid in active ulcerative colitis: a dose-finding study with newer developed mesalamine. Clin Gastroenterol Hepatol 2003, 1:36-43. A well-designed study that, unlike some other trials of aminosalicylates in UC, uses a defined primary endpoint. However, the lack of a dose-response with this formulation of mesalamine does little to clarify the optimal dosage of these drugs in UC.
5. Hanauer SB, Sninsky CA, Robinson M, et al.: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996, 124:204-211.
6. Kane S, Huo D, Aikens J, et al.: Medication nonadherehnce and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003, 114:39-43. An excellent prospective study outlining the importance of compliance to aminosalicylate therapy in quiescent UC.
7. Masuda H, Iwai S, Tanaka T, et al.: Expression on IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995, 46:111-123.
8. Nielsen OH, Gionchetti P, Ainsworth M, et al.: Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999, 94:2923-2928.
9. Saiki T, Mitsuyama K, Toyonaga A, et al.: Detection of pro- and antiinflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998, 33:616-622.
10. Gornet JM, Couve S, Hassani Z, et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003, 18:175-181.
11. Probert CSJ, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlled trial. Gut 2003, 52:998-1002.
12. Sinha A, Nightingale JM, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350-357. Despite methodologic flaws, this study informs the reader about the use of growth factors in UC. The theoretic potential for neoplastic transformation with these therapies must be recognized.
13. Hearing S, Norman M, Snyth C, et al.: Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999, 84:4149-4154.
14. Creed TJ, Norman MR, Probert CSJ, et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003, 18:65-75. An excellent paper outlining the potential for steroid-sensitizing agents in steroid-refractory UC patients.
15. Pestka S, Langer JA, Zoon KC: Interferons and their actions. Annu Rev Biochem 1987, 56:727-777.
16. Sumer N, Palabiyikoglu M: Induction of remission by IFN-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995, 7:597-602.
17. Nikolaus S, Rutgeerts P, Fedorak R, et al.: Interferon α-1a in ulcerative colitis: a placebo controlled, randomized, dose escalating study. Gut 2003, 52:1286-1290. A good paper exploring one of the new biologic therapies in UC, albeit with only modest results.
18. Sawada K: Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum 2003, 46(Suppl):S66-S77.
19. Hanai H, Watanabe F, Takeuchi K, et al.: Leukocyte adsorptive apheresis for the treatment of ulcerative colitis: a prospective, uncontrolled study. Clin Gastroenterol Hepatol 2003, 1:28-35.
20. Jo Y, Matsumoto T, Mibu R, et al.: Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis? Dis Colon Rectum 2003, 46(Suppl):S3-S9. An excellent study that provides contrasting results to previous trials with leukopharesis.
21. Lichtiger S, Present DH: Preliminary report: cyclosporine in the treatment of severe ulcerative colitis. Lancet 1990, 336:16-19.
22. D'Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120:1323-1329.
23. Van Assche G, D'Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025-1031. An outstanding paper demonstrating a similar efficacy with a lower dose of intravenous cyclosporine than has been previously used, which helps minimize potentially serious side effects.
24. Vanrenterghem Y: Tacrolimus (FK 506) in kidney transplantation. Transplant Proc 1998, 30:2171-2173.
25. van Hooff JP, Christiaans MHL: Use of tacrolimus in renal transplantation. Transplant Proc 1999, 31:3298-9.
26. Gummert JF, Ikonen T, Morris RE: Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999, 10:1366-1380.
27. Högenauer C, Wenzl HH, Hinterleitner TA, et al.: Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:415-423. A small open-label study that yielded good results with the oral agent tacrolimus in the management of severe UC, potentially providing an oral alternative to intravenous cyclosporine.
28. Schwartz DA, Sandborn WJ: Chronic pouchitis. In: Advanced Therapy of Inflammatory Bowel Disease, edn 2. Edited by Bayless TM, Hanauer SB. Hamilton, London: BC Decker Inc.; 2001:219-223.
29. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
30. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209. A well-designed randomized controlled trial showing primary prophylactic benefits of probiotics in the prevention of pouchitis after ileal pouch-anal anastomosis for UC.
31. Madsen K, Cornish A, Soper P, et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
32. Ulisse S, Gionchetti P, D'Alò S, et al.: Expression of cytokines, inducible nitric oxide synthetase and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001, 98:2691-2699.